The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

ASH Oral and Poster Presentations: 2021
ASH 2021

Oral Presentations:

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide- Scott R. Solomon, MD1, Michael T Aubrey2*, Xu Zhang, PhD3*, Katelin C Jackson1*, Christina L Roark2*, Brian M Freed2*, Lawrence E Morris, MD1, H. Kent Holland, MD1, Asad Bashey, MD, PhD1 and Melhem Solh, MD1

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches- Scott R. Solomon, MD1, Michael T Aubrey2*, Xu Zhang, PhD3*, Melhem Solh, MD1, Lawrence E Morris, MD1, H. Kent Holland, MD1, Katelin C Jackson1*, Brian M Freed2*, Christina L Roark2* and Asad Bashey, MD, PhD1

Collaborative Oral Presenations:

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study- Manali Kamdar, MD1, Scott R. Solomon, MD2, Jon E. Arnason, MD3, Patrick B. Johnston, M.D., Ph.D.4, Bertram Glass, MD5*, Veronika Bachanova, MD, PhD6, Sami Ibrahimi, MD7, Stephan Mielke, MD8, Pim G.N.J. Mutsaers, MD, PhD9*, Francisco J. Hernandez-Ilizaliturri, MD10, Koji Izutsu, MD, PhD11*, Franck Morschhauser, MD, PhD12,13*, Matthew A. Lunning, DO, FACP14, David G. Maloney, MD, PhD15, Alessandro Crotta, MD16*, Sandrine Montheard, MS17*, Alessandro Previtali, MSc16*, Lara Stepan, BS18*, Ken Ogasawara, PhD, MPH19*, Timothy Mack, PhD18* and Jeremy S. Abramson, MD.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies- Bijal D. Shah, MD1, Caron Jacobson, MD2, Scott R. Solomon, MD3,4, Nitin Jain, MD5, Mark C. Johnson, PhD6*, Monika Vainorius, MD6*, Lou Yu, PhD7*, Christopher R. Heery, MD6, Alan F. List, MD6, Fiona He, MD8,9, Ran Reshef, MD, MSc10, Luke P. Akard, MD11, Craig S. Sauter, MD12, Adam J. Olszewski, MD13, Abhinav Deol14 and Koen van Besien, MD, PhD.

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL- Nitin Jain, MD1, Hagop Kantarjian, MD1, Scott R. Solomon, MD2, Fiona He, MD3, Craig S. Sauter, MD4, Christopher R. Heery, MD5, Alan F. List, MD5, Mark C. Johnson, PhD5*, Yu Lou, MSc5*, Monika Vainorius, MD5*, Koen van Besien, MD, PhD6, Adam J. Olszewski, MD7, Anthony S. Stein, MD8 and Bijal D. Shah, MD.

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3- Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1-Michael Sebag, MD, PhD1, Noopur S. Raje, MD2, Nizar J. Bahlis, MD3, Caitlin Costello, MD4, Bhagirathbhai Dholaria, MBBS5, Melhem Solh, MD6, Moshe Y. Levy, MD7,8, Michael H. Tomasson, MD9, Harman Dube, PhD10*, Michael A. Damore, PhD10*, Hoi Ken Lon, PhD10*, Cynthia Basu, PhD11*, Athanasia Skoura, PhD12*, Edward Chan, MD13*, Suzanne Trudel, MD14, Andrzej Jakubowiak15, Michael P. Chu, MD16, Cristina Gasparetto, MD17, Andrew P. Dalovisio, MD18 and Alexander Lesokhin, MD19

Poster Presentations:

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use- Asad Bashey, MD, PhD1, Xu Zhang, PhD2*, H. Kent Holland, MD1, Lawrence E Morris Jr., MD1*, Scott R. Solomon, MD1 and Melhem Solh, MD1

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial-Scott R. Solomon, MD1, Melhem Solh, MD1, Stacey Brown, CCRP1*, Nancy Shegda1*, Katelin C Jackson1*, Xu Zhang, PhD2*, Lawrence E Morris, MD1, Asad Bashey, MD, PhD1 and H. Kent Holland, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia- Kelli McCrum, PharmD1*, Justin LaPorte, PharmD2*, Asad Bashey, MD, PhD3, Scott R. Solomon, MD3, Lawrence E Morris, MD3, H. Kent Holland, MD3 and Melhem Solh, MD3,

The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma- Melhem Solh, MD1, Asad Bashey, MD, PhD1, Lawrence E Morris, MD1, H. Kent Holland, MD1, Xu Zhang, PhD2* and Scott R. Solomon, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2 Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse, Melhem Solh, MD1, Asad Bashey, MD, PhD1, Scott R. Solomon, MD1, Lawrence E Morris, MD1, Xu Zhang, PhD2* and H. Kent Holland, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Collaborative Poster Presentations:

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML-Tomasz Rzymski, PhD1*, Urszula Pakulska, PhD1*, Camille Abboud Sr., MD2, Howard A. Burris Sr., MD3, Scott R. Solomon, MD4, Marta Obacz1*, Kristina Goller1*, Michal Combik, PhD1*, Jan Zaucha, MD, PhD5*, Milena Mazan, PhD1*, Michal Mikula, PhD6*, Magdalena Cybulska6*, Anna Polak7*, Przemyslaw Juszczynski, MD, PhD8*, Marcus Järås, PhD9, Marion Chapellier, PhD9*, Johan Flygare, MD, PhD10, Magdalena Zawadzka, PhD1*, Karolina Bukowska Strakova, PhD11*, Krzysztof Brzozka, PhD1*, Setareh Shamsili, MD, PhD1* and Noemi Angelosanto, MD.

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy- Paolo F. Caimi, MD1, Kirit M. Ardeshna, MD, MA, FRCP, FRCPath2, Erin Reid, MD, MS3, Weiyun Z. Ai, MD, PhD4, Matthew A. Lunning, DO, FACP5, Jasmine Zain, MD6, Melhem Solh, MD7, Brad S. Kahl, MD8 and Mehdi Hamadani, MD.

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma- Krish Patel, MD1, Jean-Marie Michot, MD2*, Asher Chanan-Khan, MBBS, MD3, Herve Ghesquieres, MD, PhD4*, Kamal Bouabdallah, MD5*, John C. Byrd, MD6, Guillaume Cartron, MD, PhD7*, Craig A. Portell, MD8, Melhem Solh, MD9, Hervé Tilly, MD10, William G. Wierda11, Patricia McGovern, MS12*, Chelsea Johnson, BSN, RN13*, Raman Garcha, MD12*, Vincent Ribrag, MD14, Gabriel Brisou, MD15*, David Liebowitz, MD12 and Tycel Phillips, MD.

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)- Jeremy S. Abramson, MD1, M. Lia Palomba, MD2, Leo I. Gordon, MD3, Matthew A. Lunning, DO, FACP4, Michael Wang, MD5, Jon E. Arnason, MD6, Enkhtsetseg Purev, MD, PhD7*, David G. Maloney, MD, PhD8, Charalambos Andreadis, MD, MS9, Alison R. Sehgal, MD10, Scott R. Solomon, MD11, Nilanjan Ghosh, MD, PhD12, Ana Kostic, MD13*, Yeonhee Kim, PhD13*, Ken Ogasawara, PhD, MPH14*, Christine Dehner, BSc13* and Tanya Siddiqi, MD.

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation- Camille Abboud Sr., MD1,2, Gautam Borthakur, MD3, Scott R. Solomon, MD4, Howard A. Burris Sr., MD5, Terrence Bradley, MD6, JAN Maciej Zaucha Sr.7*, Ewa Lech-Marańda, MD, PhD8*, Krzysztof Brzozka, PhD9*, Tomasz Rzymski, PhD9*, Peter Littlewood, BSc10*, Elie Mouhayar, MD11*, Setareh Shamsili, MD, PhD9* and Noemi Angelosanto, MD.

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome- Alice S. Mims, MD1, Melhem Solh, MD2, Jennifer N. Saultz, DO3, Uma Borate, MD4, Naveen Pemmaraju, MD5, Gautam Borthakur, MD5, Gail J. Roboz, MD6, Ben Powell, PhD7*, Bernice Matusow7*, Jason Halladay, PhD7*, Shireen Vali, PhD7*, Chelsea L. Hope, PhD7*, Madan G. Kundu, PhD8*, Ching Hsu, PhD8*, Paul Watkins7*, Chao Zhang, PhD7*, Jackie M. Walling, PhD, MD7, Athanasios C. Tsiatis, MD7 and Amy E. DeZern, MD.

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial- Juan Pablo Alderuccio, MD1, Weiyun Z. Ai, MD, PhD2, John Radford3*, Melhem Solh, MD4, Kirit M. Ardeshna, MD, MA, FRCP, FRCPath5, Matthew A. Lunning, DO, FACP6, Brian T. Hess, MD7, Pier Luigi Zinzani, MD, PhD8, Anastasios Stathis, MD9*, Carmelo Carlo-Stella, MD10, Mehdi Hamadani, MD11, Brad S. Kahl, MD12, David Ungar13, Turk Kilavuz14*, Eric Yu15*, Yajuan Qin15* and Paolo F. Caimi, MD.

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study- Jeremy S. Abramson, MD1, Scott R. Solomon, MD2, Jon E. Arnason, MD3, Patrick B. Johnston, M.D., Ph.D.4, Bertram Glass, MD5*, Alessandro Crotta, MD6*, Sandrine Montheard, MS7*, Alessandro Previtali, MSc6*, Fei Fei Liu, BSc, MBA8*, Julia Braverman, PhD8*, Shien Guo, PhD9*, Ling Shi, PhD9* and Manali Kamdar, MD.

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101- Claudio G. Brunstein, MD, PhD1, Paul V O’Donnell, MD2*, Brent R. Logan, PhD3*, Luciano J. Costa, MD, PhD4, Corey Cutler, MD, MPH, FRCPC5, Michael Craig, MD6, William J Hogan, MB, BCh7, Mary M. Horowitz, MD, MS3, Mitchell E. Horwitz, MD8, Chatchada Karanes, MD9, John M. Magenau, MD10*, Adriana Malone, MD11*, John M McCarty, MD12*, Joseph P. McGuirk, DO13, Lawrence E Morris, MD14, Andrew R. Rezvani, MD15, Witold Rybka16*, Rachel Beth Salit, MD17*, Sumithira Vasu, MBBS18, Mary Eapen, MBBS, MS19 and Ephraim J. Fuchs, MD, MBA.1

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial- Alessandro Paoli1*, Daniela Bellarosa, PhD1*, Alessandro Bressan1*, Francesco Bertolini, MD, PhD2, Scott R. Solomon, MD3, Pau Montesinos, PhD, MD4*, Sudipto Mukherjee, MD, PhD, MPH5, Stephen A Strickland6, Giovanni Marconi, MD7*, Armando Santoro8*, Roland B. Walter, MD9, Rachel J. Cook, MD10, Maria Calbacho, MD11*, Susana Vives12*, Salman Fazal, MD13*, Farhad Ravandi, MBBS14, Krzysztof Brzozka, PhD15*, Tomasz Rzymski, PhD15*, Milena Mazan15*, Simone Baldini, MD1*, Niccolò Ravenni1*, Monica Binaschi, PhD1*, Dirk Laurent, MD1* and Andrea Pellacani, PhD,